RemeGen completes HK$806m H share placement

RemeGen Co., Ltd. announced the completion of its H share placement on May 29, 2025, in accordance with the previously announced placing agreement. The placement of 19,000,000 new H Shares, priced at HKD42.44 per share, was successfully allotted and issued, representing approximately 3.37% of the company’s total issued shares after the placement. The company anticipates net proceeds of approximately HKD796 million from the placement. The majority, 90% or HKD716.4 million, will be directed toward research and development for its core product, Telitacicept (RC18), and expansion of its core indications by December 31, 2027. The remaining 10%, or HKD79.6 million, is designated for general corporate purposes, slated for utilization by December 31, 2025. Following the placement, RemeGen’s total issued shares increased to 563,608,243.